Wang-Rodriguez J, Rearden A
Department of Pathology 0612, University of California, San Diego, La Jolla 92093, USA.
Crit Rev Clin Lab Sci. 1995;32(4):345-76. doi: 10.3109/10408369509084688.
The complement-dependent cytotoxicity (CDC) crossmatch and the flow cytometry crossmatch (FCXM) are both used prospectively in renal transplantation, and their use is under evaluation in other types of major organ transplantation. The FCXM is the more sensitive method and better predicts outcome in second and subsequent renal allografts. Improved survival has unmasked the detrimental effect of a positive crossmatch on outcome in liver transplantation. Because of the urgent need of liver transplant candidates, it is unrealistic to defer transplantation until a crossmatch-negative donor is found; however, additional therapeutic measures may be taken to improve outcome for crossmatch-positive liver recipients. Some reports suggest that prospective crossmatching may improve outcome for sensitized heart recipients, and, additionally, recent studies have demonstrated that HLA compatibility between donor and recipient is an independent variable affecting survival after heart transplantation, prompting a reassessment of the current practice of transplanting hearts without consideration of the HLA match.
补体依赖细胞毒性（CDC）交叉配型和流式细胞术交叉配型（FCXM）在肾移植中均有前瞻性应用，并且它们在其他类型的大器官移植中的应用正在评估中。FCXM是更敏感的方法，能更好地预测第二次及后续肾移植的结果。生存情况的改善揭示了阳性交叉配型对肝移植结果的不利影响。由于肝移植候选者有迫切需求，推迟移植直到找到交叉配型阴性的供体是不现实的；然而，可以采取额外的治疗措施来改善交叉配型阳性肝移植受者的结果。一些报告表明，前瞻性交叉配型可能改善致敏心脏受者的结果，此外，最近的研究表明供体与受体之间的HLA相容性是影响心脏移植后生存的一个独立变量，促使人们重新评估目前不考虑HLA配型就进行心脏移植的做法。
